RCS - Abingdon Health PLC - CEO Interview

Abingdon HealthAnnouncement

15/03/2024 13:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240315:nRSO0916Ha&default-theme=true

RNS Number : 0916H  Abingdon Health PLC  15 March 2024

Abingdon Health plc

("Abingdon" or "the Company")

 

 

CEO interview on the Proactive Investors Platform

 

York, U.K. 15 March 2024: Abingdon Health plc (AIM: ABDX), a leading
international lateral flow contract development and manufacturing organization
(CDMO), is pleased to share a recent interview with Chris Yates, CEO of
Abingdon, on the Proactive Investors Platform.

 

Within this video Chris provides an overview of the financial and operational
highlights from Abingdon interim results which were announced on the 14 March
2024.

 

Click on the link below to watch:

https://www.proactiveinvestors.co.uk/companies/news/1043260/abingdon-health-ceo-discusses-strong-interim-results-robust-pipeline-and-growth-strategy-1043260.html
(https://www.proactiveinvestors.co.uk/companies/news/1043260/abingdon-health-ceo-discusses-strong-interim-results-robust-pipeline-and-growth-strategy-1043260.html)

 

 

Enquiries

 

 Abingdon Health plc                                         www.abingdonhealth.com/investors/ (http://www.abingdonhealth.com/investors/)
 Chris Yates, Chief Executive Officer
 Chris Hand, Non-Executive Chairman

 Singer Capital Markets (Sole Broker and Nominated Adviser)  Tel: +44 (0)20 7496 3000
 Peter Steel, Alex Bond (Corporate Finance)
 Tom Salvesen (Corporate Broking)

 

About Abingdon Health plc

 

Abingdon Health is a leading lateral flow contract development and
manufacturing organisation (CDMO) offering its services to an international
customer base across industry sectors that include clinical, animal health,
plant health, and environmental testing. Abingdon Health has the internal
capabilities to take projects from initial concept through to routine and
large-scale manufacturing; from "idea to commercial success."

 

The Company's CDMO division offers product development, regulatory support,
technology transfer and manufacturing services for customers looking to
develop new assays or transfer existing laboratory-based assays to a lateral
flow format. Abingdon Health aims to support the increase in need for rapid
results across many industries and locations and produces lateral flow tests
in areas such as infectious disease, clinical testing including companion
diagnostics, animal health and environmental testing. Faster access to results
allows for rapid decision making, targeted intervention and can support better
outcomes.

 

Abingdon Health's Abingdon Simply Test range of self-tests is an ecommerce
platform that offers a range of self-tests to empowers consumers to manage
their own health and wellbeing. The Abingdon Simply Test
(http://www.abingdonsimplytest.com) ecommerce site offers consumers a range of
information to support them in making informed decisions on the tests
available. In addition, the site provides Abingdon's contract services
customers with a potential route to market for self-tests. The Abingdon Simply
Test range is also sold through international distributors and through other
channels in the UK and Ireland such as pharmacy chains.

 

Founded in 2008, Abingdon Health is headquartered in York, England.

 

For more information visit: www.abingdonhealth.com
(http://www.abingdonhealth.com/)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAQKPBPBBKDKND